NDAORALCAPSULE, EXTENDED RELEASE
Approved
Nov 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
VERELAN PM (verapamil hydrochloride) by R-Pharm US is (l-type calcium channel blocker or calcium channel antagonist). Approved for cardiovascular disease. First approved in 1998.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VERELAN PM is an oral extended-release capsule formulation of verapamil hydrochloride, a selective L-type calcium channel blocker approved in 1998. It treats cardiovascular disease by inhibiting calcium influx into arterial smooth muscle and myocardial cells, reducing vascular resistance and cardiac contractility. The drug is indicated for hypertension and angina management.
$0.12MPart D
LOE ApproachingDeclining
Product is approaching loss of exclusivity with minimal Part D volume (269 claims), indicating a small and contracting customer base requiring defensive rather than growth-focused strategies.
Mechanism of Action
(L-type calcium channel blocker or calcium channel antagonist). Verapamil exerts its pharmacologic effects by selectively inhibiting the transmembrane influx of ionic calcium into arterial smooth muscle as well as in conductile and contractile myocardial cells without altering serum calcium…
Indications (1)
Worked on VERELAN PM at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.